Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 2/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.33 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3749441 | 0.93 | SCN9A (0.37) | PDE4DSCN9AS1PR5MEN1POLB | |
| SCHEMBL3392942 | 0.87 | PDE4D (0.39) | PDE4DSCN9AS1PR5MEN1POLB | |
| SCHEMBL13870626 | 0.87 | HRH3 (0.45) | SCN9AS1PR5MEN1KMT2AALDH1A1 | |
| SCHEMBL3392805 | 0.86 | PDE4D (0.39) | PDE4DSCN9AS1PR5MEN1POLB | |
| SCHEMBL3392789 | 0.85 | S1PR5 (0.41) | PDE4DSCN9AS1PR5MEN1KMT2A | |
| SCHEMBL3763110 | 0.83 | PDE4D (0.43) | PDE4DSCN9ALMNAKCNA3 | |
| SCHEMBL3762540 | 0.80 | SLC6A2 (0.33) | KCNA3 | |
| SCHEMBL3756873 | 0.79 | MEN1 (0.42) | MEN1POLBKMT2AKDM4EALDH1A1 | |
| SCHEMBL3757808 | 0.78 | PDE4D (0.45) | PDE4DSCN9AKCNA3 | |
| SCHEMBL3416674 | 0.78 | MEN1 (0.48) | MEN1POLBKMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202513-B2 | Aryl potassium channel blockers and uses thereof | BIONOMICS LIMITED (AU) | 2012-06-19 | — | — | US | claimed |
| US-20100297077-A1 | NOVEL ARYL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2010-11-25 | — | — | US | claimed |
| US-8202513-B2 | Aryl potassium channel blockers and uses thereof | BIONOMICS LIMITED (AU) | 2012-06-19 | — | — | US | disclosed |
| US-8202513-B2 | Aryl potassium channel blockers and uses thereof | BIONOMICS LIMITED (AU) | 2012-06-19 | — | — | US | disclosed |
| US-8202513-B2 | Aryl potassium channel blockers and uses thereof | BIONOMICS LIMITED (AU) | 2012-06-19 | — | — | US | disclosed |
| US-20100297077-A1 | NOVEL ARYL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2010-11-25 | — | — | US | disclosed |
| US-20100297077-A1 | NOVEL ARYL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2010-11-25 | — | — | US | disclosed |
| US-20100297077-A1 | NOVEL ARYL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2010-11-25 | — | — | US | disclosed |
| WO-2009043117-A1 | NOVEL ARYL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100297077-A1 | NOVEL ARYL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | KCNA3, KCNB1, KCNH3 | PDE4D 1137/4885SCN9A 106/4885S1PR5 431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.